EUVIMEDEUVIMED entdecken
Crossref

Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1

Ting Fang, Zhen Jiao, Yuting You, Jiahao Cao, Chuanzheng Wang, Jingjing Liu, Wenxiu Zhao

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Ting Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Xiamen Key Laboratory of Translational Medical of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellula…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the most common causes of malignancy-related deaths. Lenvatinib, as a multi-targeted tyrosine kinase inhibitor, has gained increasing attention for its antitumor activity. However, the effect and mechanisms of Lenvatinib on HCC metastasis are virtually unknown. In this study, we revealed that Lenvatinib inhibited HCC cell motility and epithelial mesenchymal transition (EMT), along with cell adhesion and extension. Concomitant high DNMT1 and UHRF1 mRNA levels were in HCC patients and indicated worse prognosis. On the one hand, Lenvatinib modulated the transcription of UHRF1 and DNMT1via negatively regulation of ERK/MAPK pathway. On the other hand, Lenvatinib downregulated DNMT1 and UHRF1 expression by promoting their protein degradation through ubiquitin-proteasome pathway, consequently, resulting in upregulation of E-Cadherin. Moreover, Lenvatinib attenuated Huh7 cell adhesion and metastasis in vivo. Our findings provided insight into the intriguing molecular mechanisms regarding the anti-metastasis effect of Lenvatinib in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansCell Line, TumorUbiquitinationCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticCCAAT-Enhancer-Binding ProteinsUbiquitin-Protein LigasesPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

DNMT1ERK/MAPKHepatocellular carcinomaLenvatinibUHRF1

Substanzen

CCAAT-Enhancer-Binding ProteinsUbiquitin-Protein LigaseslenvatinibPhenylurea CompoundsQuinolinesUHRF1 protein, human

Autor:innen und Institutionen

  • Xiamen Key Laboratory of Translational Medical of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Zhongshan Hospital of Xiamen University, School of Medici…
  • Xiamen Key Laboratory of Intestinal Microbiome and Human Health, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, PR China. Electronic address: jingjingliu@xmu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fang, T., Jiao, Z., You, Y., Cao, J., Wang, C., Liu, J., & Zhao, W. (2023). Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115489

Vancouver

Fang T, Jiao Z, You Y, Cao J, Wang C, Liu J, et al. Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115489

BibTeX
@article{Fang2023,
  author = {Fang, Ting and Jiao, Zhen and You, Yuting and Cao, Jiahao and Wang, Chuanzheng and Liu, Jingjing and Zhao, Wenxiu},
  title = {Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115489}
}
Kostenlos starten →